Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Levofloxacin vs Ciprofloxacin for Prophylaxis in HSCT
NCT03850379Phase 2Completed
- Sponsor
- Henry Ford Health
- Start
- Mar 2018
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of levofloxacin in bacterial infection, sponsored by Henry Ford Health. Primary endpoint: Proportion of Bloodstream Bacterial Infections at 60 days. Started Mar 2018; status: completed.
02
Drugs
levofloxacin
03
Conditions
bacterial infection
Beyond the preview
Go deeper on NCT03850379.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03850379.